Business Wire

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

Share

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.

“Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.”

BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include:

  • A network meta-analysis comparing the efficacy of BRUKINSA vs acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL); and
  • A post-hoc analysis from the Phase 3 ALPINE study of BRUKINSA vs ibrutinib evaluating the risk of developing hypertension based on the initiation and adjustment of antihypertensive medications.

Reflecting BeiGene’s growing solid tumor development program, TEVIMBRA (tislelizumab-jsgr) will be the subject of multiple presentations – as a monotherapy, in combination with chemotherapy agents, and as part of immunotherapy regimens across a range of tumor types. Key highlights include:

  • New data from the Phase 3 RATIONALE-306 study evaluating TEVIMBRA plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC); and
  • Initial data from a first-in-human study evaluating HPK1 inhibitor BGB-15025 alone and in combination with TEVIMBRA.

“Our data at ASCO are a testament to the potential versatility of TEVIMBRA across a range of tumor types, and we are excited by the momentum of this critical pillar of our solid tumor development program,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “During the meeting, we look forward to sharing a new analysis from our RATIONALE-306 study, which will provide insights into the three-year efficacy and safety of TEVIMBRA as a first-line treatment for ESCC.”

BeiGene Presentations During ASCO 2024

Abstract Title

Abstract #

Presentation Details

Lead Author

Hematology

Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA)

7048

Session Type and Title: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: June 3 at 9:00 AM-12:00 PM CDT

M. Shadman

Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)

11158

Session Type and Title: Poster Session – Quality Care/Health Services Research

Session Date and Time: June 3 at 9:00 AM-12:00 PM CDT

M. Krackeler

Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis

N/A

Online

D. Ramirez

Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia (CLL) patients (pts) treated with Bruton tyrosine kinase inhibitors (BTKi): A real-world data study using the Symphony Health Solution database

N/A

Online

T. Kou

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL

N/A

Online

J. Pinilla-Ibarz

Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma

N/A

Online

B. Shah

Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis

N/A

Online

T. Munir

Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL)

7072

Session Type and Title: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: June 3 at 9:00 AM-12:00 PM CDT

K. Yang

Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)

N/A

Online

S. Gaballa

Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices

N/A

Online

J. Hou

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia

TPS7090

Session Type and Title: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: June 3 at 9:00 AM-12:00 PM CDT

H. Lee

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL

TPS7087

Session Type and Title: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: June 3 at 9:00 AM-12:00 PM CDT

M. Shadman

Solid Tumor/IO

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up

4032

Session Type and Title: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Session Date and Time: June 1 at 1:30-4:30 PM CDT

H. Yoon

BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors

2610

Session Type and Title: Poster Session – Developmental Therapeutics—Immunotherapy

Session Date and Time: June 1 at 9:00 AM-12:00 PM CDT

L. Yufei

Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study

3599

Session Type and Title: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Session Date and Time: June 1 at 1:30-4:30 PM CDT

K. Ding

Tislelizumab First-Line (1L) Gastric/Gastroesophageal Junction Cancer (G/GEJ) Treatment Efficacy on PRO-Based Symptom Endpoints Adjusting for Informative Missing Data Bias: Results from RATIONALE 305

2605

Session Type and Title: Poster Session – Developmental Therapeutics—Immunotherapy

Session Date and Time: June 1 at 9:00 AM-12:00 PM CDT

D. Serrano

A first‑in‑human phase 1a dose‑escalation study of BGB‑15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody) in patients (pts) with advanced solid tumors

2585

Session Type and Title: Poster Session – Developmental Therapeutics—Immunotherapy

Session Date and Time: June 1 at 9:00 AM-12:00 PM CDT

S. Deva

Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

N/A

Online

C. Zhou

About BRUKINSA® (zanubrutinib)
BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

Please see full U.S. Prescribing Information for BRUKINSA® (zanubrutinib), including U.S. Patient Information or visit www.brukinsa.com.

About TEVIMBRA® (tislelizumab-jsgr)
Tislelizumab is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

Please see full U.S. Prescribing Information for TEVIMBRA® (tislelizumab-jsgr), including Medication Guide.

About Sonrotoclax (BGB11417)
Sonrotoclax is an investigational small molecule B-cell lymphoma 2 (BCL2) inhibitor. It belongs to a class of BCL2 homology 3 (BH3) mimetics, and preclinical and IND-enabling studies have demonstrated potent activity and high selectivity of sonrotoclax against the antiapoptotic protein BCL2. Sonrotoclax is more potent and selective for BCL2 relative to BCLxL than venetoclax and shows the potential to overcome common BCL2 resistance mutations.

About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the strength and future growth of BeiGene’s oncology portfolio; BeiGene’s ability to develop treatments that address the unmet needs of patients with B-cell malignancies and solid tumors; the versatility of tislelizumab across tumor types; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products;BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Contact:
Liza Heapes
+1 857-302-5663
ir@beigene.com

Media Contact:
Kyle Blankenship
+1 667-351-5176
media@beigene.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AgroAmerica Unveils PlanetA: A Step Forward in Sustainable Food Businesses23.5.2024 19:58:00 CEST | Press release

This year marks a significant milestone for AgroAmerica, a family-owned, vertically integrated company that provides sustainable food and ingredients globally. AgroAmerica proudly launches PlanetA, an ambitious new sustainability strategy aimed at driving tangible change and redefining the paradigms of sustainable food systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523124865/en/ PlanetA - Sustainability Strategy (Photo: Business Wire) PlanetA emerges from the fusion of AgroAmerica's essence with a profound focus on the planet, underscoring the company's strong commitment to sustainable practices. It embodies the idea that Earth is our only home and everyone’s responsibility, highlighting AgroAmerica's action plan to nurture the planet: our shared home. Under the visionary leadership of AgroAmerica's CEO, Fernando Bolaños, the company embarks on a transformative journey with PlanetA. This comprehensive strategy ad

Canva Unveils Enterprise Era With Powerful New Workplace Products Debuted at Canva Create23.5.2024 18:30:00 CEST | Press release

At its first international Canva Create event in Los Angeles today, Canva, the world’s only all-in-one visual communication platform, accelerated its focus on the enterprise, debuting the platform’s biggest overhaul in a decade alongside a range of new workplace products and services poised to redefine the way millions of people work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523849577/en/ Canva Enterprise (Photo: Business Wire) "We are excited to introduce a revamped Canva experience and a suite of new products to empower every organisation to design,” said Melanie Perkins, co-founder and CEO of Canva. “As demand for visual content soars, navigating organizational complexity is more challenging than ever. We democratized the design ecosystem in our first decade and now look forward to unifying the fragmented ecosystems of design, AI, and workflow tools for every organization in our second decade.” As visual communic

Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair23.5.2024 18:03:00 CEST | Press release

Mary Kay Inc., a corporate cheerleader in support of STEM education and youth pursuing their dreams, recently awarded three grants to five standout high school scientists, selected from nearly 2,000 participants representing almost 70 countries, with grants at the Regeneron International Science & Engineering Fair (ISEF) in Los Angeles. The grants—totaling nearly $10,000—were awarded to students with innovative projects focused on finding cures for cancers affecting women, sustainable packaging innovation, and protecting our planet’s most valuable resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523366610/en/ Mary Kay Inc. proudly served as a Special Award Organization for the 2024 Regeneron International Science and Engineering Fair, awarding three cash prizes to inspiring young scientists. (Graphic: Society for Science, Regeneron ISEF) ISEF, a program of Society for Science for over 70 years, is the world’s lar

Spatial Adds HOOPS Communicator23.5.2024 18:00:00 CEST | Press release

Spatial Corp, the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announced today that it has added HOOPS Communicator, developed by Tech Soft 3D, to complement and extend its portfolio of component technologies. With the addition of HOOPS Communicator to Spatial’s 3D components portfolio, Spatial now enables web-based visualization of and interaction with 3D data for a diverse range of design, engineering and manufacturing workflows. Adding HOOPS Communicator to Spatial’s product portfolio allows its customers to expand their applications to the web while reusing their IP from traditional desktop applications. As a result, Spatial’s customers can leverage many new opportunities on the web, including extended customer-reach, more access control, and less costly distributions, updates and maintenance. “We are excited to enhance our portfolio by adding HOOPS Communicator. This addition enables Spatia

WORLD’S MOST ICONIC ROCK BAND, THE ROLLING STONES, SELECTS THUNDER RIDGE NATURE ARENA AS DESTINATION FOR FINAL NORTH AMERICAN PERFORMANCE23.5.2024 18:00:00 CEST | Press release

Bass Pro Shops Big Cedar Lodge announced today that on July 21 the Ozarks will rock as the ancient hills, valleys and lakes never have when the world’s greatest rock-and-roll band, The Rolling Stones, light up Thunder Ridge Nature Arena for the last performance on their final North American tour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523211894/en/ Rendering of Thunder Ridge Nature Arena (Graphic: Business Wire) The concert promises to be one of the most memorable and highly anticipated concert events ever. It is a pairing of the World’s Greatest Rock-and-Roll Band and the most breathtaking and awe-inspiring outdoor amphitheater in all of North America. The Thunder Ridge concert stop is part of the “Hackney Diamonds Tour ’24” for The Rolling Stones, which includes 20 performances in 16 cities. Tickets will go on sale Friday, May 31, and will be available at ThunderRidgeNatureArena.com. “We’re honored to host The R

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye